Payment overview · 2025
General Payments
$754.01
42 reported records · 13 companies
Healthcare provider profile · identity verified
Jonathan Trego Swank, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ABINGDON, VA · NPI 1750459228
Verified facts
What the public records show
CMS Open Payments records show Jonathan Trego Swank, MD received $754.01 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $193.29 | 25.6% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $93.00 | 12.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.86 | 12.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.57 | 10.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.54 | 7.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.82 | 6.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.90 | 5.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.05 | 4.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $30.99 | 4.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.86 | 4.1% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $24.10 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.55 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.48 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $754.01 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $113.70 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $93.00 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.38 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.57 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.43 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.43 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.54 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.54 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.82 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.99 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 297 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 243 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
143 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
243 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 669 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 656 | 176 |
| Losartan Potassium | Losartan Potassium | 653 | 161 |
| Gabapentin | Gabapentin | 637 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 512 | 127 |
| Omeprazole | Omeprazole | 492 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 451 | 126 |
| Potassium Chloride | Potassium Chloride | 420 | 90 |
| Metformin Hcl | Metformin Hcl | 404 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 393 | 107 |
| Pravastatin Sodium | Pravastatin Sodium | 372 | 94 |
| Alprazolam | Alprazolam | 350 | 45 |
| Trazodone Hcl | Trazodone Hcl | 342 | 87 |
| Furosemide | Furosemide | 339 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 323 | 86 |
| Montelukast Sodium | Montelukast Sodium | 317 | 71 |
| Famotidine | Famotidine | 308 | 70 |
| Eliquis | Apixaban | 297 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 297 | 78 |
| Prednisone | Prednisone | 286 | 149 |
| Simvastatin | Simvastatin | 285 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 283 | 54 |
| Allopurinol | Allopurinol | 243 | 67 |
| Ozempic | Semaglutide | 243 | 39 |
| Glipizide Er | Glipizide | 232 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 60 |
| Tramadol Hcl | Tramadol Hcl | 226 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 52 |
| Sertraline Hcl | Sertraline Hcl | 200 | 48 |
| Atenolol | Atenolol | 194 | 44 |
| Ezetimibe | Ezetimibe | 194 | 56 |
| Clonazepam | Clonazepam | 193 | 23 |
| Carvedilol | Carvedilol | 170 | 44 |
| Spironolactone | Spironolactone | 163 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 158 | 41 |
| Meloxicam | Meloxicam | 149 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 20 |
| Azithromycin | Azithromycin | 143 | 109 |
| Trulicity | Dulaglutide | 143 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 37 |
| Propranolol Hcl | Propranolol Hcl | 139 | 26 |
| Glimepiride | Glimepiride | 137 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 44 |
| Lorazepam | Lorazepam | 128 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 125 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 125 | 31 |
| Buspirone Hcl | Buspirone Hcl | 123 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 115 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 28 |
| Bupropion Xl | Bupropion Hcl | 111 | 25 |
| Metformin Hcl Er | Metformin Hcl | 111 | 28 |
| Cephalexin | Cephalexin | 107 | 67 |
| Finasteride | Finasteride | 103 | 27 |
| Ibuprofen | Ibuprofen | 101 | 30 |
| Topiramate | Topiramate | 101 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 70 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 19 |
| Memantine Hcl | Memantine Hcl | 96 | 20 |
| Amoxicillin | Amoxicillin | 92 | 65 |
| Torsemide | Torsemide | 91 | 21 |
| Celecoxib | Celecoxib | 90 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 22 |
| Warfarin Sodium | Warfarin Sodium | 88 | 21 |
| Meclizine Hcl | Meclizine Hcl | 87 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 66 |
| Pregabalin | Pregabalin | 82 | 16 |
| Mirtazapine | Mirtazapine | 80 | 20 |
| Fluconazole | Fluconazole | 79 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 20 |
| Jardiance | Empagliflozin | 77 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 22 |
| Ondansetron Odt | Ondansetron | 71 | 22 |
| Promethazine Hcl | Promethazine Hcl | 70 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 17 |
| Enalapril Maleate | Enalapril Maleate | 67 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 66 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 12 |
| Glipizide | Glipizide | 62 | 20 |
| Diazepam | Diazepam | 57 | suppressed |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Xarelto | Rivaroxaban | 50 | 15 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Estradiol | Estradiol | 48 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 11 |
| Terazosin Hcl | Terazosin Hcl | 47 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 12 |
| Nystatin | Nystatin | 43 | 20 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 14 |
| Linzess | Linaclotide | 40 | 13 |
| Klor-Con M10 | Potassium Chloride | 39 | 15 |
| Naproxen | Naproxen | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 14 |
| Loperamide | Loperamide Hcl | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Sucralfate | Sucralfate | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 11 |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Methimazole | Methimazole | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 12 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $754.01 · 42 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAMZYOS, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Hizentra, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error